Cannabis quotidien et autres consommations en période de confinement CANNAVID Etude de l’impact du Covid19 sur les usages, les pratiques et la santé des consommateurs réguliers de cannabis Responsables de la recherche : CSAPA – CAARUD Bus 31/32 Maëla Lebrun Gadelius maela.lebrun@bus3132.org Plus Belle La Nuit Victor Martin victor.martin@plusbellelanuit.org Le Bus 31/32 et Plus Belle La Nuit (PBLN) vous proposent de participer à l’étude intitulée « CANNAVID » : Etude de l’impact du Covid19 sur les usages, les pratiques et la santé des consommateurs réguliers de cannabis. En quoi consiste cette étude ? L’objectif principal de cette recherche est d’évaluer l’impact du confinement dû au Covid19 sur vos consommations de cannabis et sur votre santé. Egalement, [...]
Lire la suiteCannabis use and the course and outcome of major depressive disorder : A population based longitudinal study FEINGOLD D., REHM J., LEV-RAN S. Psychiatry Research, 2017, 251, 225-234. Doi : 10.1016/j.psychres.2017.02.027 Highlights • Individuals with baseline major depressive disorder were followed over a three-year time period. • Cannabis users and individuals with cannabis use disorders were compared to nonusers. • No differences were found in rates of remission between the groups. • Level of cannabis use was associated with significantly more depressive symptoms at follow-up. • These findings did not retain significance after adjusting for baseline confounding factors. Abstract Cannabis use has been reported to affect [...]
Lire la suiteShort-term effects of cannabis consumption on cognitive performance in medical cannabis patients Phillip Olla, Nicholas Rykulski, Jessica L. Hurtubise, Stephen Bartol, Rachel Foote, Laura Cutler, Kaitlyn Abeare, Nora McVinnie, Alana G. Sabelli, Maurissa Hastings, and Laszlo A. Erdodi Applied Neuropsychology : Adult, 2019, 1-11. Doi : 10.1080/23279095.2019.1681424 ABSTRACT This observational study examined the acute cognitive effects of cannabis. We hypothesized that cognitive performance would be negatively affected by acute cannabis intoxication. Twenty-two medical cannabis patients from Southwestern Ontario completed the study. The majority (n¼13) were male. Mean age was 36.0 years, and mean level of education was 13.7 years. Participants were administered the same brief neurocognitive battery three times during [...]
Lire la suiteQuality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases : A 12-Month Longitudinal Study. BOUSO J.C., JIMENEZ-GARRIDO D., ONA G., WOZNICA D., dos SANTOS R.G., HALLAK J.E.C., PARANHOS B. A., de ALMEIDA MENDES F., YONAMINE M. et al. : Phytotherapy Research, 2020. Doi : 10.1002/ptr.6639 © 2020 John Wiley & Sons, Ltd. Abstract The number of patients using cannabis for therapeutic purposes is growing worldwide. While research regarding the treatment of certain diseases/disorders with cannabis and cannabinoids is also expanding, only a few longitudinal studies have assessed the mid-term impacts of medical cannabis use on psychological variables and quality [...]
Lire la suiteCannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction Selena N. Clem, Teresa L. Bigand, Marian Wilson Pain Management Nursing, 2019, 1-5. Doi : 10.1016/j.pmn.2019.06.009 a b s t r a c t Background : Cannabis has been linked to reduced opioid use, although reasons for cannabis use among adults prescribed opioids are unclear. Aims : The purpose of this study was to determine whether motivations for cannabis use differ between adults prescribed opioids for persistent pain versus those receiving opioids as medication-assisted treatment for opioid use disorder. Design : A cross-sectional survey design was used. Participants : Adults prescribed opioids for persistent pain (n [...]
Lire la suiteBenefits and adverse effects of cannabis use among adults with persistent pain Teresa Bigand, Cristina Lee Anderson, Mary Lee Roberts, Michele Rose Shaw, Marian Wilson Nursing Outlook, 2 0 1 9 , 67, 2 2 3 -2 3 1 doi : 10.1016/j.outlook.2018.12.014. A B S T R A C T Background : Increasingly, states are legalizing cannabis for recreational use. Improved accessibility may allow adults with pain to use cannabis more liberally. Greater understanding is needed about how adults with pain perceive the effects of cannabis, particularly those who also use opioid analgesics. Purpose : To examine the perceived effects of cannabis among adults who have [...]
Lire la suiteOpioid mortality following implementation of medical marijuana programs (1999-2017) in the United States Daniel E. Kaufman, Asawer M. Nihal, Janan D. Leppo, Kelly M. Staples, Kenneth L. McCall, Brian J. Piper BioRxiv preprint, June 14, 2019. Doi : 10.1101/670059 Abstract The United States is in the midst of an opioid overdose epidemic. A prior report using the Center for Disease Control’s Wide-ranging Online Data for Epidemiologic Research (WONDER) database discovered that opioid overdoses decreased by 24.8% from 1999 to 2010 in states with medical cannabis (MC+) relative to those without (MC-). The present study evaluated any differences following MC legislation on WONDER reported opioid overdoses, [...]
Lire la suiteCannabis Use and Cognition in Adults Prescribed Opioids for Persistent Pain Megan Wildes, Teresa L. Bigand, Matthew E. Layton, , Marian Wilson Pain Management Nursing, 2019, 1-6. Doi : 10.1016/j.pmn.2019.06.014 a b s t r a c t Background : Adults with persistent pain frequently report cannabis use to help manage their symptoms. The impact of cannabis use on cognition in the presence of concurrent symptoms of depression and anxiety is poorly understood. Aims : Our study explored how cannabis use affects relationships among symptoms of depression, anxiety, and cognition. Design : A cross-sectional survey study was conducted. Settings : Surveys were distributed at outpatient clinics treating adults [...]
Lire la suiteBibliographie : Cannabinoïdes et Douleurs Docteur Christian Sueur, GRECC, avril 2020 1 – Cannabinoïdes et douleurs : 1 - 4 2 - Cannabinoïdes et douleurs aigües : 5 3 – Cannabinoïdes et douleurs chroniques (non-cancéreuses) : 6 - 8 4 - Cannabinoïdes et douleurs neuropathiques : 9 - 12 5 - Cannabinoïdes et douleurs cancéreuses : 13 – 15 6 - Cannabinoïdes et « alternatives » aux opiacés : 16 - 17
Lire la suiteRenaud Colson est docteur en droit, diplômé des universités de Nantes et de Cardiff, et des Facultés Saint-Louis de Bruxelles. Il est maître de conférences à la faculté de droit et des sciences politiques de l’université de Nantes, British Academy visiting fellow et honorary lecturer à l’université de Cardiff. Il a développé ses recherches à l’Institut universitaire européen (Florence, de 2011 à 2013), à l’université Jawaharlal Nehru (New Delhi, 2016), à l’Institut universitaire sur les dépendances (Montréal, 2018), et au Max-Planck-Institut für ausländisches und internationales Privatrecht (Hambourg, 2019). Renaud Colson travaille à la croisée de diverses disciplines (droit processuel, droit pénal européen, [...]
Lire la suite